Johannes Gerardus Chri Schikan Sells 7,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 7,000 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $30.05, for a total value of $210,350.00. Following the sale, the director directly owned 388,167 shares of the company’s stock, valued at approximately $11,664,418.35. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.

Pharvaris Price Performance

PHVS stock traded up $1.25 during trading on Friday, reaching $28.54. 129,619 shares of the stock traded hands, compared to its average volume of 172,220. The business’s 50 day moving average price is $27.39 and its 200-day moving average price is $25.80. Pharvaris N.V. has a 52-week low of $14.59 and a 52-week high of $30.24. The firm has a market capitalization of $1.87 billion, a PE ratio of -8.47 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, equities research analysts predict that Pharvaris N.V. will post -3.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

PHVS has been the subject of several analyst reports. Wall Street Zen downgraded Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday. Royal Bank Of Canada decreased their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Finally, Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and an average target price of $42.73.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the last quarter. Amundi grew its holdings in shares of Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after purchasing an additional 7,879 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.